Seamless solution in AML

Why Cyclacel, FDA devised novel protocol for AML Phase III

In an effort to overcome recruiting challenges for elderly patients with acute myelogenous leukemia, Cyclacel Pharmaceuticals Inc. and FDA agreed on a SPA for a registrational Phase III study that incentivizes enrollment with an active comparator not approved for the indication in the U.S., coupled with an open-label design that encourages patients in the experimental arm to stay in the trial.

Sapacitabine is an analog of the nucleoside cytosine that induces apoptosis of cancer cells in two ways: interfering with DNA synthesis and repair by homologous recombination, and slowing transit through the cell cycle.

Cyclacel is studying the cell cycle modulator in the Phase III SEAMLESS trial in patients aged 70 years or older with newly diagnosed AML who are not candidates for

Read the full 1218 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE